Hi! @peggydobbs :

Oncotype DX test is a genomic test for early-stage, ER-positive, HER2-negative breast cancer that analyzes 21 genes in tumor tissue to predict the likelihood of cancer recurrence and the potential benefit of chemotherapy. I am so sorry that your first Oncologist seemed to miss the mark by telling you that it was not done for people over 70 thus delaying the treatment with Kisqali :(. Thank God that you changed your medical oncologist!

As for Signatera blood test for cancer patients, it is a personalized tool (custom-built for each patient by analyzing their specific tumor tissue to identify unique mutations), tumor-informed molecular residual disease (MRD) blood test by Natera (company name) that detects circulating tumor DNA (ctDNA) to track cancer recurrence (if there's any), and evaluate the effectiveness of this patient's ongoing cancer treatments. It is used to detect MRD after surgery for cancer patients with solid tumors, such as: colorectal, breast, lung, and muscle-invasive bladder cancer. This test is ordered by a physician, requiring both a tissue sample (from the patient's tumor) and regular blood draws (typically every 3 months) from the patient with stage II-IV cancers, as well as immunotherapy monitoring.

Sorry for such a lengthy note, hope it helps... I was over 70 when I had my surgery on 12/26/2023, and my surgeon sent my tumor tissue for an oncotype test right after the surgery. I am not qualified for a regular Signatera blood test; however, my PCP agrees with me to set up quarterly blood tests to check my tumor markers, such as: CA 15-3, etc., to make sure that my ongoing treatments plan is on the right track. I am very grateful for my kind-hearted PCP walking extra miles with me to assure me peace of mind!

Wishing you all a better journey ahead!